1	A systematic review of sample size estimation accuracy on power in
2	malaria cluster randomised trials measuring epidemiological
3	outcomes
4	
5	Authors & Affiliations
6	
7	Joseph Biggs ^{1#} , Joseph D. Challenger ² , Joel Hellewell ² , Thomas S. Churcher ² & Jackie Cook ¹
8	1. Medical Research Council (MRC) International Statistics and Epidemiology group,
9	Department of Infectious Disease Epidemiology and International Health, London School
10	of Hygiene and Tropical Medicine, London, UK
11	2. Medical research Council (MRC) Centre for Global Infectious Disease Analysis,
12	Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College
13	London, London, UK
14	# Corresponding author: joseph.biggs1@lshtm.ac.uk
15	Email contacts
16	 joseph.biggs1@lshtm.ac.uk
17	• j.challenger@imperial.ac.uk
18	• joel@ebi.ac.uk
19	 thomas.churcher@imperial.ac.uk
20	 jackie.cook@lshtm.ac.uk
21	
22	
23	
24	
25	
26	
-	
27	
28	

- 29 Abstract
- 30

31 Introduction

Cluster randomised trials (CRTs) are the gold standard for measuring the community-wide impacts of
 malaria control tools. CRTs rely on well-defined sample size estimations to detect statistically
 significant effects of trialled interventions; however these are often predicted poorly by investigators.
 Here, we review the accuracy of predicted parameters used in sample size calculations for malaria
 CRTs with epidemiological outcomes.

37 Methods

38 We searched for published malaria CRTs using four online databases in March 2022. Eligible trials 39 included those with malaria-specific epidemiological outcomes which randomised at least six 40 geographical clusters to study arms. Predicted and observed sample size parameters were extracted 41 by reviewers for each trial. Pair-wise correlation coefficients were calculated to assess the accuracy 42 of predicted control-arm outcome estimates and desired relative reductions (effect sizes) between 43 arms compared to what was observed. Among trials which retrospectively calculated an estimate of 44 heterogeneity in cluster outcomes, we recalculated study power according to observed trial 45 estimates.

46 Results

47 Of the 1889 records identified and screened, 108 articles were eligible and comprised of 71 malaria 48 CRTs. Among trials that included sample size calculations (91.5%, 65/71), most estimated cluster 49 heterogeneity using the coefficient of variation (k) (80%, 52/65) which were often predicted without 50 using prior data (67.7%, 44/65). Predicted control-arm epidemiological outcomes correlated weakly 51 with those observed, with 61.2% (19/31) of prevalence estimates overestimated. Among the 52 minority of trials which retrospectively calculated cluster heterogeneity (20%, 13/65), empirical 53 values contrasted with those used in sample size estimations and often compromised study power. 54 Observed effect sizes were often smaller than had been predicted at the sample size stage (72.9%, 55 51/70) and were typically higher in the first, compared to the second, year of trials. Overall, effect 56 sizes achieved by malaria interventions tested in trials decreased between 1995 and 2021.

57 Conclusions

58 Study findings reveal sample size parameters in malaria CRTs were often inaccurate and resulted in

59 underpowered studies. Future trials must strive to obtain more representative epidemiological

60 sample size inputs to ensure interventions against malaria are adequately evaluated.

61	Registration
62	This review is registered with PROSPERO (CRD42022315741).
63	
64 65	Keywords
66	Malaria; Cluster randomised trial; sample size; heterogeneity; coefficient of variation
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	

91 Introduction

92

93 Malaria is a parasitic disease that in 2022 was responsible for the deaths of 608,000 individuals 94 worldwide; most of whom were children in Sub-Saharan Africa [1]. There are numerous, effective 95 interventions that can be used to combat malaria transmission that are recommended by the World 96 Health Organisation (WHO). To generate evidence for the recommendation of these tools, cluster 97 randomised trials (CRTs) are conducted to demonstrate the community-wide impacts [2]. 98 Historically, CRTs have been instrumental in demonstrating the mass effects of the first insecticide-99 treated bed nets (ITNs) [3-5], mass chemoprevention strategies [4, 6], and most recently, dual-100 action, long-lasting insecticide treated nets (LLINs) [7, 8]. Despite their necessity, CRTs are subject to 101 major constraints. Trialling interventions over large geographical areas is costly, logistically 102 challenging, and at the design stage, requires well-defined estimates of underlying transmission 103 patterns in the study setting [9]. Consequently, in recent years, some malaria CRTs have reported 104 being underpowered and have presented inconclusive findings [10-14]. 105 Investigators power CRTs according to sample size estimations which account for cluster-level 106 randomisation, where groups of people, as opposed to individuals, are randomised to receive 107 interventions. This design can result in heterogeneity of outcomes between and within clusters 108 owing to groups of individuals, such as households, schools, and geographical areas, sharing similar 109 biological and socio-economic characteristics which introduces correlation in study outcomes [15, 110 16]. Consequently, cluster heterogeneity needs to be incorporated into sample size estimations, 111 along with expected control arm transmission and effect size estimates (relative percentage 112 reductions between arms), to compensate for the lower precision associated with this design. The 113 between- and within-cluster heterogeneity can be measured using the coefficient of variation (k) or 114 intra-cluster correlation coefficient (ICC), respectively, and heavily impacts trial size [15, 16]. Trialling 115 new interventions in areas with missing or inadequate data results in investigators having to rely on 116 judgement-based estimates for their sample size estimations which may be inaccurate. 117 Numerous reviews have evaluated sample size estimations in CRTs focused on cancer treatments 118 [17], school-based interventions [18], oral health [19], residential care [20] and CRTs in general [21]. 119 These reviews highlighted that despite trials mostly including sample size estimations, not all 120 calculations accounted for cluster heterogeneity (73% [17], 78% [18], 71% [19] and 47% [20]). Two of 121 these reviews further explored whether trials also included empirical measures of cluster

- heterogeneity and compared them to prior estimates [18, 21]. Both reviews highlighted trials rarely
- 123 provided retrospective estimates of cluster heterogeneity (<40%), and among trials that did, large

124 differences were identified between predicted and observed estimates. This suggests many trialists

125 misclassified the true degree of cluster heterogeneity at the design stage. Finally, one review

126 explored which trials stated their desired effect sizes and compared them to those observed [21].

127 They showed that 68% of desired effect sizes were overestimated. Interestingly, none of these

128 reviews compared the outcome measures predicted and observed in the control arms of their

129 included trials. This is crucial as misclassification of predicted effect size, cluster heterogeneity and

130 control-arm outcome measurements all impact study power [15, 16, 22].

131 Malaria transmission is driven by numerous environmental and socio-economic factors including

rainfall, temperature, vegetation cover, type of housing and provision of malaria interventions [23-

133 26]. Consequently, transmission is often spatially and temporally variable across various

134 geographical scales. This presents a challenge for malaria CRTs as heterogenous transmission in the

135 community may result in spatial/temporal variability in malaria-specific outcomes between

136 geographical clusters. Therefore, estimating the level of malaria transmission in the control arm and

137 the degree of cluster heterogeneity for malaria CRT sample size estimations is difficult in the

absence of baseline data.

139 In this review, our aim was to investigate the characteristics and quality of sample size estimations in

140 malaria CRTs that used geographical clusters. Specifically, we explored whether study investigators

accurately predicted sample size estimation parameters, including control-arm transmission, cluster

142 heterogeneity, and desired effect sizes, according to observed measurements during trials. It is

143 hoped results from this review will improve future study design and help ensure trialists are able to

accurately detect impacts of interventions that are vital in the fight against malaria.

145 Methods

146

147 Search strategy and selection criteria

148

149 We conducted a systematic review of published malaria CRTs with epidemiological outcomes. In 150 March 2022, we searched the database systems Pubmed, Web of Science, Embase and Cochrane 151 reviews using truncated versions of the terms 'malaria' and 'cluster randomised trial' for trials 152 published in English language. The bibliographies of identified reviews were additionally screened 153 according to title and abstract. Search results were imported into the reference manager Endnote 154 where digitally identified duplicates were removed. Manually identified duplicates were removed by 155 two reviewers (JB & JH). Pre-determined eligibility criteria were used to screen identified articles 156 based on title and abstract (JB & JH) while screening discordance was adjudicated by consensus (TC

- 157 & JC). Identified studies were eligible for inclusion if they met the following criteria: the study was a
- 158 CRT wherein at least six geographical clusters were randomised to intervention and control arms;
- 159 the study measured malaria-specific epidemiological outcomes. Such outcomes include malaria
- 160 prevalence or incidence according to microscopy, rapid diagnostic tests (RDTs), or molecular
- 161 methods. Trials that only measured anaemia and all-cause mortality were excluded as these
- 162 outcomes could be attributed to other conditions. Prior to study initiation, the review was registered
- 163 in PROSPERO on 9th March 2022 (CRD42022315741).

164 Data extraction

- 165
- 166 Two reviewers (JB & JH) independently extracted information from the final list of studies. Extraction
- 167 discrepancies were resolved by consensus with TC and JC. Data for sample size estimations and
- 168 empirical outcomes were extracted for all epidemiological outcomes measured at all trial timepoints.
- 169 For each trial, we extracted data on overall trial design, randomisation method and type of
- 170 intervention evaluated. For each sample size estimation, we extracted data on all assumptions
- 171 outlined as well as those used to estimate cluster heterogeneity. To compare sample size
- assumptions to observed trial outcomes, where data was available, we extracted arm-aggregated
- 173 malaria prevalence (cases/survey population) and/or incidence data (cases/person-years) by trial
- 174 year and overall.
- 175

176 Data analysis

177

For each sample size estimation where observed prevalence/incidence data were available, we calculated the relative reduction (effect size) between intervention arms for the duration of each study and stratified by year. The effect size was calculated according to equations *A* and *B* where subscript (1) and (2) represent the control and intervention arms, respectively, while (r) and (p) correspond to malaria incidence per person year and malaria prevalence, respectively. In this manner, the effect size represents the % relative reduction between the control and the intervention arm.

- 185Prevalence effect size = $1 p_2/p_1$ eq. A186Incidence effect size = $1 r_2/r_1$ eq. B
- 187 For sample size parameters including control-arm prevalence, incidence and effect size estimates,
- 188 pair-wise Pearson's correlation coefficients were used to calculate the strength of association

189 between those estimated and observed for trials (Rho, p-value<0.05). To determine whether 190 parameters were accurately estimated by investigators, we calculated the relative percentage 191 difference between estimates and observed outputs. Parameters were classified as 192 overestimated/underestimated if they exceeded a relative percentage difference of 10%. Regarding 193 cluster heterogeneity estimates (k/ICC) provided in trials, we first investigated whether estimates 194 based on pilot or baseline data differed to estimates based on no data. A pair-wise t-test was used to 195 determine whether the mean value difference equalled zero. Among trials that reported cluster 196 heterogeneity using observed trial data, we recalculated study power (%) according to the observed 197 k/ICC and year 1 control arm prevalence/incidence but using the desired effect size quoted in the 198 paper. The remaining sample size parameters used were identical to the original power calculations: 199 desired effect size (%), cluster size, cluster number and significance level (%). Study power for CRTs 200 was calculated according to methods described by Hayes and Moulton in [15]. All analyses were 201 conducted in STATA (v.17, Texas, USA).

202 **Results**

203

204 Our literature search yielded 1889 records from database searching and 145 records from the

bibliographies of Cochrane reviews (Figure 1). Following the removal of duplicates, a total of 1302

206 records were screened after which 991 were excluded as they were not concerned with malaria

207 CRTs. The remaining 311 records were assessed for eligibility resulting in 108 published articles being

208 included in this study, which comprised of 71 malaria CRTs (Additional file 1). The review PRISMA

209 2020 checklist is included in additional file 2.



- 211
- 212

213

Figure 1: Study selection of included epidemiological malaria CRTs

214

215 The trial-level characteristics of the 71 malaria CRTs are shown in Table 1 and Figure 2A-G. Since 216 1995, the number of malaria-specific CRTs have increased in frequency and distribution across the 217 world (Figure 2A&B). The 71 identified CRTs were conducted in a total of 78 countries, with study 218 sites in Africa (N:53), Asia (N:21) and South America (N:4). 54.9% (39/71) of the trials evaluated 219 vector control interventions, all measured Plasmodium falciparum outcomes while 26.8% (19/71) 220 also measured Plasmodium vivax outcomes. Most trials adopted a parallel design (85.9%, 61/71) and 221 consisted of two study arms (77.5%, 55/71). Concerning the cluster randomisation procedures, 222 39.4% (28/71) used simple randomisation to allocate clusters, 23.9% (17/71) implemented stratified 223 randomisation, 22.5% (16/71) employed restricted randomisation, while 12.7% (9/71) randomised 224 clusters within matched pairs. Among trials that randomised clusters through pair-matching or stratification, most restricted allocation based on a single criterion. For those that utilised restricted 225 226 randomisation, most used between 3-4 restriction criteria (Figure 2F). The most common restriction

- criteria used for randomisation included cluster transmission intensity (prevalence or incidence),
- cluster size, location, and historical intervention coverage (Figure 2G). Regarding cluster design,
- 229 74.6% (53/71) adopted a basic cluster design, 14.1% (10/71) used a 'fried egg' design and 11.3%
- 230 (8/71) reported ensuring a minimum buffer distance between clusters. Among trials that reported
- their minimum cluster buffer size, 72.7% (8/11) reported a minimum buffer size <2km while those
- who stated a minimum cluster separation reported a range between no separation and 3 km.
- 233

 Table 1: Overall characteristics of malaria CRTs identified in the systematic review (N:71)

Trial characteristics	n	%
Intervention type		
Community engagement	1	1.4
Drug	26	36.6
Drug & Vector	5	7.0
Vector	39	54.9
Primary outcome		
Incidence	39	54.9
Prevalence	32	45.1
Malaria species		
P. falciparum	52	73.2
P. falciparum & P. vivax	19	26.8
Design		
Parallel	61	85.9
Factorial	4	5.6
Crossover	2	2.8
Stepped wedge	4	5.6
Randomisation method		
Block	1	1.4
Pair matched	9	12.7
Restricted	16	22.5
Simple	28	39.4
Stratified	17	23.9
Number of study arms		
2	55	77.5
3	9	12.7
4	7	9.9
Cluster type		
Basic	53	74.6
Buffered	8	11.3
Fried egg	10	14.1
Level of analysis		
Cluster	23	32.4
Individual	48	67.6
Formal sample size equation ^a		
Yes	53	74.6

No	18	25.4
Reported being underpowered	l _p	
Yes	17	23.9
No	54	76.1

a: accounted for cluster heterogeneity b: reported at the end of the trial



Figure 2: Characteristics of malaria CRTs identified in this review. A: Distribution of malaria CRTs. B:
 Annual frequency of malaria CRTs. C: Overall duration of malaria CRTs (dash line: mean). D: Size of
 buffers around study clusters. E: Minimum separation between study clusters. F: Number of

239 restriction criteria used according to the type of trial randomisation. G: The most utilised restriction 240 criteria in malaria CRTs. Population willingness refers to population acceptance of trialled 241 interventions. Sample size assumptions used in trials with prevalence as the outcome measure: H: 242 Predicted control-arm prevalence compared to desired effect size. I: The desired total number of 243 individuals surveyed per cluster. J: Required number of clusters per arm. K: the predicted coefficient of 244 variation (k) for prevalence stratified by whether values were estimating using prior or baseline data 245 (D) or assumed using no data (ND). Vertical dash: mean. Sample size assumptions used in trials with 246 incidence as the outcome measure: L: Predicted control-arm incidence per person compared to 247 desired effect size (pa: per annum). M: The desired person-years per cluster. N: Required number of 248 clusters per arm. O: the predicted coefficient of variation (k) for incidence stratified by whether values 249 were based on prior or baseline data (D) or assumed using no data (ND). Vertical dash: mean.

250

251 Among the included 71 CRTs, a total of 65 formal cluster sample size estimations were conducted 252 that accounted for cluster heterogeneity by including a k, ICC or design effect component. Of these, 253 34/65 were based on incidence while 31/65 were based on prevalence (Table 2 & Figure 2H-O). The 254 remaining trials either did not account for cluster heterogeneity or lacked any sample size 255 justification. Over 90% of all sample size estimations were calculated to achieve at 80% power 256 (59/65) at the 5% significance level (60/65). Concerning the epidemiological outcome measures in 257 the control arm, most investigators predicted incidence using prior data (70.6%, 24/34) while most 258 investigators predicted prevalence without using prior data (54.8%, 17/31). Regarding sample size 259 estimations based on prevalence (N: 31), investigators estimated a range of prevalences in the 260 control arm (mean: 0.21, range: 0.05 - 0.48) and desired effect sizes (mean: 47.1% range: 17.5 - 95%) 261 which tended to be higher in low prevalence settings (Figure 2H). The average required cluster 262 sample size was 104.5 individuals (Median 80; Figure 2I) and average required number of clusters per 263 arm equalled 17.5 (Figure 2J). For sample size estimations based on incidence (N: 34), a range of 264 incidence estimates in the control arm were estimated (range: 0.002 - 2.6 cases per person per 265 annum (pa)). Desired effect sizes (%) were similarly higher in lower incidence settings (mean: 41.1%, 266 range 20 - 93%) (Figure 2L). The average cluster size for incidence was 415 (median: 125) person 267 years (Figure 2M) while the mean number of required clusters per arm was 17.6 (Figure 2N).

- 268**Table 2**: Characteristics of sample size estimations used in malaria CRTs stratified by outcome269measure: prevalence or incidence. There were a total of 65 sample size estimations, 34 based on
- 270

incidence outcomes while 31 based on prevalence outcomes.

Sample size	Overal	I	Incide	ence	Prevalence		
characteristics	N:65		N:34		N:31		
	n	%	n	%	n	%	
Desired power (%)							
80-90	59	90.8	29	85.3	30	96.8	

90-100	6	9.2	5	14.7	1	3.2
Significance level (%)						
10	1	1.5	0	0.0	1	3.2
5	60	92.3	32	94.1	28	90.3
2.5	2	3.1	1	2.9	1	3.2
1.67	2	3.1	1	2.9	1	3.2
Cluster heterogeneity measure						
ICC	10	15.4	6	17.6	4	12.9
Design effect	3	4.6	2	5.9	1	3.2
k (CV)	52	80.0	26	76.5	26	83.9
Method used to estimate						
cluster heterogeneity						
With data ^ª	21	32.3	9	26.5	12	38.7
Without data	44	67.7	25	73.5	19	61.3
Method used to estimate						
control-arm transmission						
With data ^ª	38	58.5	24	70.6	14	45.2
Without data	27	41.5	10	29.4	17	54.8
Retrospectively estimated						
cluster heterogeneity						
Yes	13	20.0	5	14.7	8	25.8
Νο	52	80.0	29	85.3	23	74.2
Diagnostic used						
PCR	10	15.4	3	8.8	7	22.6
RDT	29	44.6	17	50.0	12	38.7
Microscopy	19	29.2	10	29.4	9	29.0
Mixed	7	10.8	4	11.8	3	9.7
Age range tested (years)						
<5	15	23.1	8	23.5	7	22.6
<10	14	21.5	9	26.5	8	25.8
<15	7	10.8	10	29.4	9	29.0
All ages	29	44.6	11	32.4	10	32.3

a: estimated using baseline or prior data

271

272 The most common cluster heterogeneity measure used in malaria CRT sample size calculations was

the coefficient of variation (k) (80% 52/65). 67.7% (44/65) of estimated cluster heterogeneity

274 measures were estimated with no prior data while only 32.3% (21/65) were estimated using baseline

275 or pilot study data. Lastly, only a minority of investigators retrospectively calculated cluster

heterogeneity using trial data (20%, 13/65) (Table 2).

277 Control arm transmission intensity assumptions

278

279 We explored how accurately epidemiological outcomes were predicted in the control arms of

280 included trials (prevalence N: 31, incidence N: 34). Throughout each of the trials, predicted

281 prevalence and incidence only moderately positively correlated with corresponding observed values 282 (incidence r: 0.49, p-value<0.05, prevalence r: 0.39, p-value<0.05) (Figure 3A&B). Moreover, most 283 predicted prevalence and incidence estimates were overestimated by more than 10% according to 284 observed estimates (prevalence overestimation: 61.1% (19/31); incidence overestimation: 50% 285 (17/34)) (Figure 3C&D). We also assessed whether using prior data was better for predicting 286 subsequent prevalence/incidence. Results revealed no different between using prior data or not 287 (Figure 3A&B). Lastly, we found predicted prevalence/incidence correlated significantly with those 288 observed in first year of each trial yet not the second year (Figure 3E&F). These results demonstrate 289 investigators tended to poorly predict control-arm prevalence/incidence, particularly in the second 290 year and that prevalence was often overestimated in malaria CRTs.



292

293 Figure 3: Accuracy of predicted versus observed prevalence and incidence outcomes in malaria CRT 294 control arms. A & B: Correlation between the predicted and overall observed prevalence/incidence 295 stratified by method used to predict estimates: using data (D; blue) using no data (ND; red) and combined (black). r: correlation coefficient. C & D: The percentage of predicted prevalence/incidence 296 297 estimates that were underestimated (relative percentage difference <-10%), no difference (relative 298 percentage difference -10% to 10%) or overestimated (relative percentage difference >10%) 299 according to overall observed estimates. E & F: Correlation matrix comparing the predicted 300 prevalence/incidence with estimates observed throughout the trial (observed), in year 1 (Observed 301 y1) and in year 2 (Observed y2). *: r p-value<0.05.

302

Cluster heterogeneity assumptions

303

Among trials that utilised the coefficient of variation (k) to account for cluster heterogeneity of incidence/prevalence in their sample size estimations (Table 2), a range of values were used (mean: 0.37, range: 0.1 - 1.0) (Figure 2K&O). Values of k predicted using prior data were, on average, statistically higher than those predicted with no prior data (no prior data mean k: 0.30; prior data mean k: 0.52, t-test p-value<0.05). This suggests k was likely underestimated in many trials. A small number of trials used the ICC to account for cluster heterogeneity, and they similarly had a large range (mean: 0.12, range: 0.006 – 0.40) (Additional file 3).

311 Among the trials that additionally calculated k/ICC at the end of the study using empirical data (20% 312 13/65), we explored whether predicted cluster heterogeneity estimates were accurate and then used 313 the measured value for k/ICC to recalculate study power (Table 3). Empirical cluster heterogeneity 314 estimates often differed to those used in sample size estimations with the majority underestimating 315 k/ICC (61.5% 8/13). Recalculated power estimates, according to the stated desired effect, observed 316 control arm transmission intensity and k/ICC, were often lower than originally planned for. The 317 observed power for 7/11 trials was below 80%. For 4/11 trials, cluster heterogeneity was 318 overestimated which resulted in them remaining suitably powered to detect their desired effect 319 sizes. We were unable to replicate power calculations for two of the trials that provided retrospective 320 k/ICC estimates [27, 28]. It should be noted it was not always stated which timepoint/subset of trial 321 data was used to retrospectively calculate k/ICC. 322 Table 3: The study power (%) to detect desired effect sizes according to predicted (left) and observed 323 (right) sample size parameters among trials the retrospectively calculated cluster heterogeneity. The 324 predicted sample size parameters include the predicted control-arm prevalence/incidence and the

- k/ICC values stated in the article methods. The observed sample size parameters include the empirical
 control-arm prevalence/incidence and k/ICC values in the first year of the trials. First year data was
- 327 utilised to estimate observed study power to account for temporal variations in transmission/cluster
- 328 heterogeneity. The remaining sample size parameters including clusters per arm, cluster size and
- 329 significance level were identical between the predicted and observed power calculations. Blue: study
- 330

power >80%. Red: Study power <80%.

Trial Desire		Predicted sample size parameters				Observed sample size parameters (year 1)					
	effect	Control	Control			Power	Control	Control			Power
	size (%)	prevalence	incidence ^a	k	ICC	(%)	prevalence	incidence ^a	k ^b	ICCp	(%)
Samuels 2021	50	0.40		0.30		98	0.39		0.15		>99.9
Chaccour 2021	30		1.40	0.50		80		5.16	0.34		99
Staedke 2020	17.5	0.40		0.30		84	0.14		0.86		19
Bradley 2016	50	0.28		0.25		>99.9	0.23		0.59		45
Cisse 2016				0.30		n/a			0.66		n/a
Sluydts 2016	40	0.05		0.50		93	0.05		1.00		63
Bousema 2016	66.6	0.15		0.40		82	0.12		0.50		64
Pinder 2015	30		0.24	0.40		94		0.56	0.74		49
West 2014	33.3	0.09		0.25		84	0.26		0.26		98
Poespoprodjo 2021	66.6		0.30		0.05	89		0.86		0.07	>99.9
Foy 2019	28.8		2.25		0.02	87		2.49		0.059	61
Oldenburg 2018	30	0.10			0.075	n/a	0.51			0.1	n/a
von Seidlein 2019 (Vietnam) ^c	95	0.10			0.07	84	0.04			0.003	>99.9
von Seidlein 2019 (Cambodia)	° 95	0.10			0.07	84	0.02			0.005	87
von Seidlein 2019 (Laos) ^c	95	0.10			0.07	84	0.11			0.035	99
von Seidlein 2019 (Myanmar) ^c	95	0.10			0.07	84	0.08			0.082	68

a: incidence per person per year

b: not always stated which subset of data used to calculate k/ICC

c: ICC retrospectively calculated at country level

331

332 Effect size assumptions

334	Among the 71 included malaria CRTs, a total of 70 desired effect size estimates were accompanied
335	with empirical effect size estimates. We examined whether the desired effect sizes used in sample
336	size estimations corresponded to observed effect sizes in malaria CRTs. We identified no evidence of
337	a correlation between desired and observed effects sizes throughout the trial (r=0.21, p: 0.09) (Figure
338	4A). We also found that 72.7% (51/70) of desired effect sizes overestimated by more than a relative
339	10% difference (Figure 4B). We then explored factors that may have contributed to these findings.
340	Firstly, among trials that were conducted for at least 2 years (N:36), we found a strong positive
341	correlation between year 1 and year 2 observed effect sizes (r=0.49; p:0.003) (Figure 4C). Despite
342	this, effect sizes were more often higher in the first, compared to the second, year of each trial
343	(52.8% 19/36) (Figure 4C). Secondly, after comparing observed effect sizes to trial start date, a

344 negative correlation was seen (r: -0.30, p<0.05), suggesting that effect sizes have been decreasing



345 over time (Figure 4D).



346

347 Figure 4: Accuracy of desired versus observed effect size (ES) estimates in malaria CRTs. A: Correlation 348 between the desired and overall observed effect size by type of intervention. Diagonal dash: line of 349 equality. **B**: The percentage of desired effect size estimates that were underestimated (relative 350 percentage difference <-10%), no difference (relative percentage difference -10% to 10%) or 351 overestimated (relative percentage difference >10%) according to overall observed effect size estimates. **C**: Correlation of observed effect size estimates by the 1^{st} and 2^{nd} year of the trial by type 352 of intervention. Diagonal dash: line of equality **D**: The percentage of observed effect size estimates 353 that were higher in the 1^{st} or 2^{nd} year of the trial (relative percentage difference>10%) or were no 354 355 different (relative percentage difference<10%). E: D: Correlation between the overall observed effect 356 size estimates versus the trial starting year by type of intervention. Horizontal dash: cut off line for 357 positive effect size. Above this line epidemiological outcomes were lower in the intervention, 358 compared to the control arms, of trials.

359 Discussion

- 361 Results from this review reveal malaria CRTs, measuring epidemiological outcomes, often rely on
- 362 poorly defined sample size assumptions which results in compromised study power. Well powered
- 363 trials need accurate information on predicted transmission intensity in the control arm, the

estimated heterogeneity of outcomes between or within clusters and desired effect size between
 study arms. We found that transmission intensity and effect sizes were often over-estimated, with
 measures of cluster heterogeneity commonly misclassified. To ensure future malaria CRTs are
 adequately powered to detect the impacts of control interventions, efforts need to be made to
 ensure sample size parameters are more reliably estimated at the trial design stage.

369 Our finding that most desired effect sizes in malaria CRTs were overestimated corresponds with 370 results from a separate review of 300 non-disease specific CRTs which found 68% of trials 371 experienced lower effect sizes than anticipated [21]. Authors speculated this over-estimation was 372 likely attributed to trials being powered to detect minimally important differences between study 373 arms and/or ineffective interventions being trialled. These are common challenges for malaria CRTs 374 too. A 30% effect size was previously documented as the threshold for an intervention to have public 375 health relevance and be cost-effective according to the WHO. These are likely highly ambitious 376 targets for certain interventions [2], particularly when being compared to already effective 377 interventions. Moreover, some trialists concluded their interventions were simply inadequate to curb 378 malaria transmission [12, 29, 30]. It should be noted that malaria CRTs have also suggested other 379 factors, unrelated to study power, that impeded their ability to demonstrate an impact including low 380 coverage/adherence [31, 32], inappropriate study settings [33, 34] and poor quality control [35].

381 In this review we further explored patterns in observed effect sizes among malaria CRTs and revealed 382 effect size estimates tended to be higher in the first compared to the second year of trials. This 383 implies the adherence and community-wide impact of certain trialled interventions wane over time. 384 For interventions such as bed nets, recent studies in Tanzania [36], Nigeria [37] and Nicaragua [38] 385 have demonstrated net coverage, usage, physical integrity and insecticidal activity all decreased 386 within a two-year period. Secondly, our results highlight observed effect sizes have, overall, 387 decreased since the 1990s. This is likely a consequence of trialled interventions being increasingly 388 layered over existing, widespread standard-of-care for malaria. Historically, control arms in malaria 389 CRTs consisted of either no or substandard interventions including untreated nets and placebo 390 treatments [3, 39, 40]. Recently however, control arms of trials typically include numerous, effective 391 malaria interventions [12, 41-43] and sometimes only differ from intervention arms with regards to 392 regiment [42, 44]. Together, these factors likely resulted in effect sizes being overstated.

Predicting malaria transmission intensity in the control arms of CRTs is challenging given the disease
is so spatially and temporally heterogeneous [24, 25]. Here, we found no evidence that estimating
control-arm transmission intensity using prior data provided a more accurate measures of prevalence
or incidence in control arms at the end of trials. Moreover, estimated transmission intensity

correlated with transmission more closely in the first, compared to the second, year of the trials. This
is likely the consequence of environmental, seasonal, socio-economic, and behavioural changes that
impact both human and mosquito populations [45, 46], and highlights the challenge in forecasting
short term malaria transmission patterns [47-51].

401 In this review only 20% of included malaria CRTs retrospectively calculated cluster heterogeneity 402 using trial data which resembles the previous review of 300 CRTs in general that found only 11% 403 provided empirical cluster heterogeneity estimates [21]. Moreover, the finding that the majority of 404 observed cluster heterogeneity measures differed to those inputted into sample size equations is 405 concerning as study power is so heavily impacted by between/within cluster correlation [15]. Future 406 malaria trials should adhere to CONSORT guidelines and provide empirical estimates of cluster 407 heterogeneity to both inform future trials and assist reviewers in determining whether trials are 408 adequately powered to detect their desired impact [21]. Moreover, given a recent secondary analysis 409 of a malaria CRT in Tanzania demonstrated temporal changes in within-cluster cluster heterogeneity 410 during the intervention period [52], providing empirical estimates of cluster heterogeneity at various 411 timepoints during trials may further help decipher whether trials were adequately powered 412 throughout the trial period [53]. As only a few malaria trials provided retrospective estimates of 413 k/ICC, we were unable to investigate whether basing estimates on prior data or not assists in 414 accurately characterising cluster heterogeneity. Moreover, it was not always clear which subset of 415 the data k/ICC measures referred to and investigators may have been prompted to present observed 416 cluster heterogeneity measures if the interventions failed to show impact. Consequently, 417 characterising the true degree of cluster heterogeneity among a representative sample of malaria 418 CRTs to inform future trials remains an imperative area of continued investigation.

419 **Conclusion**

420

- Results from this review demonstrate the accuracy of epidemiological inputs in malaria CRT sample/power size calculations require improvement. By simply reporting empirical cluster heterogeneity measures alongside published results, in line with CONSORT guidelines, future trials may be better informed to estimate suitable sample sizes. Determining trial transmission intensity and heterogeneity in the control arm remains a larger challenge given the sporadic nature of malaria transmission. Without more representative sample size parameters, future CRTs are at risk of being underpowered to detect the impacts of vital, novel control tools against malaria.
- 428 List of abbreviations

429

430	CRT	Cluster randomised trial					
431	ES	Effect size					
432	ICC	Intracluster correlation coefficient					
433	IRS	Indoor residual spraying					
434	ITN	Insecticide-treated bed nets					
435	k	coefficient of variation					
436	LLIN	Long-lasting insecticidal nets					
437	ра	Per annum					
438	PCR	Polymerase chain reaction					
439	ру	Person-year					
440	RDT	Rapid diagnostic test					
441	WHO	World Health Organisation					
442							
443 444	Declarations						
445	Ethics	approval and consent to participate					
446	Not ap	plicable					
447							
448	Consent for publication						
449	Not applicable						
450							
451	Availa	bility of data and materials					
452 453	The dat corresp	tasets generated and/or analysed during the current study are available from the bonding author on reasonable request.					
454							
455	Comp	eting interests					
456	The authors declare that they have no competing interests.						
457	Funding						

- 458 This research is supported by a grant to the London School of Hygiene and Tropical Medicine from
- the Bill & Melinda Gates Foundation (INV-038132). JDC, JH, and TC also acknowledge funding from
- the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK
- 461 Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global
- 462 Health EDCTP3 Joint Undertaking. The funders had no role in study design, data collection and
- analysis, decision to publish or preparation of the manuscript.
- 464

465 Authors' contributions

- 466 Study conception: JC and TC. Literature searching and extraction: JB and JH. Data analysis: JB and
- 467 JDC. Supervision: JC & TC. Manuscript preparation: JB. Manuscript editing and review: JB, JDC, TC and
- 468 JC. The authors read and approved the final manuscript.

469 Acknowledgements

470 Not applicable

471 **References**

472

473 WHO, World malaria report 2023. 2023, World Health Organisation: Geneva. 1. 474 2. WHO, How to design vector control efficacy trials: guidance on phase III vector control field 475 trial design. 2017, World Health Organization. 476 3. Kroeger, A., et al., Insecticide-impregnated bed nets for malaria control: varying experiences 477 from Ecuador, Colombia, and Peru concerning acceptability and effectiveness. Am J Trop Med 478 Hyg, 1995. **53**(4): p. 313-23. 479 4. Nevill, C.G., et al., Insecticide-treated bednets reduce mortality and severe morbidity from 480 malaria among children on the Kenyan coast. Tropical Medicine & amp; International Health, 481 2007. **1**(2): p. 139-146. 482 5. ter Kuile, F.O., et al., Impact of permethrin-treated bed nets on malaria, anemia, and growth 483 in infants in an area of intense perennial malaria transmission in western Kenya. Am J Trop 484 Med Hyg, 2003. 68(4 Suppl): p. 68-77. 485 6. Tagbor, H., et al., The clinical impact of combining intermittent preventive treatment with 486 home management of malaria in children aged below 5 years: cluster randomised trial. 487 Tropical Medicine & International Health, 2011. 16(3): p. 280-289. 488 7. Protopopoff, N., et al., Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal 489 net and indoor residual spray interventions, separately and together, against malaria 490 transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two 491 factorial design trial. Lancet, 2018. **391**(10130): p. 1577-1588. 492 8. Tiono, A.B., et al., Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, 493 versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-494 resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet, 2018. 495 **392**(10147): p. 569-580. 496 9. Dron, L., et al., The role and challenges of cluster randomised trials for global health. Lancet 497 Glob Health, 2021. 9(5): p. e701-e710. Homan, T., et al., The effect of mass mosquito trapping on malaria transmission and disease 498 10. 499 burden (SolarMal): a stepped-wedge cluster-randomised trial. Lancet, 2016. 388(10050): p. 500 1193-201.

501	11.	Samuels, A.M., et al., Impact of Community-Based Mass Testing and Treatment on Malaria
502		Infection Prevalence in a High-Transmission Area of Western Kenya: A Cluster Randomized
503		<i>Controlled Trial.</i> Clin Infect Dis, 2021. 72 (11): p. 1927-1935.
504	12.	Sangoro, O., et al., A cluster-randomized controlled trial to assess the effectiveness of using
505		15% DEET topical repellent with long-lasting insecticidal nets (LLINs) compared to a placebo
506		lotion on malaria transmission. Malar J, 2014. 13 : p. 324.
507	13.	Shekalaghe, S.A., et al., A cluster-randomized trial of mass drug administration with a
508		gametocytocidal drug combination to interrupt malaria transmission in a low endemic area
509		in Tanzania. Malar J, 2011. 10 : p. 247.
510	14.	Sochantha, T., et al., Insecticide-treated bednets for the prevention of Plasmodium falciparum
511		malaria in Cambodia: a cluster-randomized trial. Trop Med Int Health. 2006. 11(8): p. 1166-
512		77.
513	15.	Hayes, R.J. and S. Bennett, Simple sample size calculation for cluster-randomized trials. Int J
514		Epidemiol, 1999. 28 (2): p. 319-26.
515	16.	K Hemming, S.E., G Forbes, C Weijer, M Taljaard, How to design efficient cluster randomised
516		trials. Research methods and reporting, 2017. 358 .
517	17.	Murray, D.M., et al., Design and analysis of group-randomized trials in cancer: a review of
518		current practices. J Natl Cancer Inst, 2008. 100(7): p. 483-91.
519	18.	Parker, K., et al., Characteristics and practices of school-based cluster randomised controlled
520		trials for improving health outcomes in pupils in the UK: a systematic review protocol. BMJ
521		Open, 2021. 11 (2): p. e044143.
522	19.	Froud, R., et al., Quality of cluster randomized controlled trials in oral health: a systematic
523		review of reports published between 2005 and 2009. Community Dent Oral Epidemiol, 2012.
524		40 Suppl 1 : p. 3-14.
525	20.	Diaz-Ordaz, K., et al., A systematic review of cluster randomised trials in residential facilities
526		for older people suggests how to improve quality. BMC Med Res Methodol, 2013. 13: p. 127.
527	21.	Rutterford, C., et al., Reporting and methodological quality of sample size calculations in
528		cluster randomized trials could be improved: a review. J Clin Epidemiol, 2015. 68(6): p. 716-
529		23.
530	22.	Eldridge, S.M., D. Ashby, and S. Kerry, Sample size for cluster randomized trials: effect of
531		coefficient of variation of cluster size and analysis method. Int J Epidemiol, 2006. 35(5): p.
532		1292-300.
533	23.	Baidjoe, A.Y., et al., Factors associated with high heterogeneity of malaria at fine spatial scale
534		in the Western Kenyan highlands. Malar J, 2016. 15 : p. 307.
535	24.	Gwitira, I., et al., Spatial and spatio-temporal analysis of malaria cases in Zimbabwe. Infect
536		Dis Poverty, 2020. 9 (1): p. 146.
537	25.	Knudson, A., et al., Spatio-temporal dynamics of Plasmodium falciparum transmission within
538		a spatial unit on the Colombian Pacific Coast. Sci Rep, 2020. 10 (1): p. 3756.
539	26.	Selvaraj, P., E.A. Wenger, and J. Gerardin, Seasonality and heterogeneity of malaria
540		transmission determine success of interventions in high-endemic settings: a modeling study.
541		BMC Infect Dis, 2018. 18 (1): p. 413.
542	27.	Cisse, B., et al., Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten
543		Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLoS Med, 2016.
544		13 (11): p. e1002175.
545	28.	Oldenburg, C.E., et al., Annual Versus Biannual Mass Azithromycin Distribution and Malaria
546		Parasitemia During the Peak Transmission Season Among Children in Niger. Pediatr Infect Dis
547		J, 2018. 37 (6): p. 506-510.
548	29.	Tiono, A.B., et al., A controlled, parallel, cluster-randomized trial of community-wide
549		screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina
550		<i>Faso.</i> Malar J, 2013. 12 : p. 79.

551	30.	Sutanto, I., et al., Negligible Impact of Mass Screening and Treatment on Mesoendemic
552		Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial. Clin
553		Infect Dis, 2018. 67 (9): p. 1364-1372.
554	31.	Tagbor, H., et al., The clinical impact of combining intermittent preventive treatment with
555		home management of malaria in children aged below 5 years: cluster randomised trial. Trop
556		Med Int Health, 2011. 16 (3): p. 280-9.
557	32.	Desai, M.R., et al., Impact of Intermittent Mass Testing and Treatment on Incidence of
558		Malaria Infection in a High Transmission Area of Western Kenya. Am J Trop Med Hyg, 2020.
559		103 (1): p. 369-377.
560	33.	Bousema, T., et al., The Impact of Hotspot-Targeted Interventions on Malaria Transmission in
561		Rachuonvo South District in the Western Kenvan Hiahlands: A Cluster-Randomized Controlled
562		<i>Trial</i> , PLoS Med, 2016, 13 (4): p. e1001993.
563	34.	Magris, M., et al., Community-randomized trial of lambdacyhalothrin-treated hammock nets
564		for malaria control in Yanomami communities in the Amazon region of Venezuela. Trop Med
565		Int Health, 2007, 12 (3); p. 392-403.
566	35.	Keating, J., et al., Evaluating indoor residual spray for reducing malaria infection prevalence
567		in Eritrea: results from a community randomized control trial. Acta Trop. 2011. 119 (2-3): p.
568		107-13.
569	36.	Lorenz, L.M., et al., Comparative functional survival and equivalent annual cost of 3 lona-
570		lastina insecticidal net (LLIN) products in Tanzania: A randomised trial with 3-year follow up.
571		PLoS Med. 2020. 17 (9); p. e1003248.
572	37.	Obi, E., et al., Monitoring the physical and insecticidal durability of the long-lasting
573		insecticidal net DawaPlus((R)) 2.0 in three States in Nigeria, Malar J. 2020. 19 (1): p. 124.
574	38.	Villalta, E.L., et al., Evaluation of the durability and use of long-lasting insecticidal nets in
575		<i>Nicaragua</i> . Malar J, 2021. 20 (1): p. 106.
576	39.	Misra, S.P., et al., Malaria control: bednets or spraying? Spray versus treated nets using
577		deltamethrina community randomized trial in India. Trans R Soc Trop Med Hyg, 1999. 93 (5):
578		p. 456-7.
579	40.	von Seidlein, L., et al., The effect of mass administration of sulfadoxine-pyrimethamine
580		combined with artesunate on malaria incidence: a double-blind, community-randomized,
581		placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg, 2003. 97 (2): p. 217-25.
582	41.	Bradley, J., et al., A cluster randomized trial comparing deltamethrin and bendiocarb as
583		insecticides for indoor residual spraying to control malaria on Bioko Island, Equatorial
584		<i>Guinea</i> . Malar J, 2016. 15 (1): p. 378.
585	42.	Poespoprodjo, J.R., et al., Supervised versus unsupervised primaquine radical cure for the
586		treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised,
587		controlled, open-label superiority trial. Lancet Infect Dis, 2022. 22 (3): p. 367-376.
588	43.	Chaccour, C., et al., Incremental impact on malaria incidence following indoor residual
589		spraying in a highly endemic area with high standard ITN access in Mozambique: results from
590		a cluster-randomized study. Malar J, 2021. 20 (1): p. 84.
591	44.	Foy, B.D., et al., Efficacy and risk of harms of repeat ivermectin mass drug administrations for
592		control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet, 2019. 393 (10180): p.
593		1517-1526.
594	45.	Deutsch-Feldman, M., et al., Spatial and epidemiological drivers of Plasmodium falciparum
595		malaria among adults in the Democratic Republic of the Congo. BMJ Glob Health, 2020. 5(6).
596	46.	Yamba, E.I., et al., Climate Drivers of Malaria Transmission Seasonality and Their Relative
597		Importance in Sub-Saharan Africa. Geohealth, 2023. 7 (2): p. e2022GH000698.
598	47.	Bath, D., et al., Effectiveness and cost-effectiveness of reactive, targeted indoor residual
599		spraying for malaria control in low-transmission settings: a cluster-randomised, non-
600		inferiority trial in South Africa. The Lancet, 2021. 397 (10276); p. 816-827.

601	48.	Merkord, C.L., et al., Integrating malaria surveillance with climate data for outbreak
602		detection and forecasting: the EPIDEMIA system. Malar J, 2017. 16 (1): p. 89.
603	49.	Pourtois, J.D., et al., Climatic, land-use and socio-economic factors can predict malaria
604		dynamics at fine spatial scales relevant to local health actors: Evidence from rural
605		Madagascar. PLOS Glob Public Health, 2023. 3 (2): p. e0001607.
606	50.	Tompkins, A.M., et al., Dynamical Malaria Forecasts Are Skillful at Regional and Local Scales
607		in Uganda up to 4 Months Ahead. Geohealth, 2019. 3 (3): p. 58-66.
608	51.	Zinszer, K., et al., A scoping review of malaria forecasting: past work and future directions.
609		BMJ Open, 2012. 2 (6).
610	52.	Ouyang, Y., et al., Accounting for complex intracluster correlations in longitudinal cluster
611		randomized trials: a case study in malaria vector control. BMC Med Res Methodol, 2023.
612		23 (1): p. 64
613	53.	Pinder, M., et al., Efficacy of indoor residual spraying with dichlorodiphenyltrichloroethane
614		against malaria in Gambian communities with high usage of long-lasting insecticidal
615		mosquito nets: a cluster-randomised controlled trial. Lancet, 2015. 385 (9976): p. 1436-46.